Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Ribrag V, et al. Among authors: koscielny s. Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11. Lancet. 2016. PMID: 27080498 Clinical Trial.
BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
Camara-Clayette V, Koscielny S, Roux S, Lamy T, Bosq J, Bernard M, Fest T, Lazar V, Lenoir G, Ribrag V. Camara-Clayette V, et al. Among authors: koscielny s. PLoS One. 2013 Sep 12;8(9):e73993. doi: 10.1371/journal.pone.0073993. eCollection 2013. PLoS One. 2013. PMID: 24069261 Free PMC article.
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V. Michot JM, et al. Among authors: koscielny s. Eur J Cancer. 2015 Nov;51(16):2386-95. doi: 10.1016/j.ejca.2015.07.009. Epub 2015 Aug 5. Eur J Cancer. 2015. PMID: 26254810
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Ribrag V, et al. Among authors: koscielny s. Blood. 2009 Apr 2;113(14):3307-13. doi: 10.1182/blood-2008-03-148874. Epub 2008 Sep 3. Blood. 2009. PMID: 18768784 Free article.
A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment.
Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P, Monhonval M, Pereira R, Bosq J, Ribrag V, Vantelon JM, Munck JN. Girinsky T, et al. Among authors: koscielny s. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):148-55. doi: 10.1016/s0360-3016(01)01626-1. Int J Radiat Oncol Biol Phys. 2001. PMID: 11516864
217 results